Professor Hong-Hu Zhu got his Ph.D. from Peking University under the supervision of Professor Daopei Lu, an academician of the Chinese Academy of Engineering. He is a member of the International Acute Promyelocytic Leukemia (APL) Foundation, a member of the Asia‐Pacific Leukemia Consortium, a standing committee member of the Hematology-Oncology Committee of the Chinese Anti-Cancer Association, an executive committee member of the China Association of Chinese Medicine Blood Disease Branch, a committee member of the Leukemia and Lymphoma Group of Chinese Society of Hematology in Chinese Medical Association, and the deputy director of the Cell Analysis Committee, Chinese Society of Biotechnology.

Professor Zhu has worked in hematology for 29 years, specializing in clinical and translational research in acute leukemia. His primary academic achievements include:

First, establishing a unique chemo-free outpatient treatment model with oral arsenics ad ATRA for acute promyelocytic leukemia (APL), with a cure rate of more than 95%.【J Clin Oncol(2013)、N Eng J Med(2014a，2014b)、Lancet Oncol(2018)、Blood(2016, 2018, 2019),J Hematol Oncol(2022)】

Second, establishing the DAV (daunorubicin, cytarabine, and homoharringtonine) regimen as front-line treatment for newly diagnosed acute myeloid leukemia (AML), with a complete remission  rate exceeding 90%.【Lancet Haematol 2022】

Third, Pioneering the definition of a new subtype of leukemia, RARG rearranged AML for the first time internationally.【Leukemia 2018、Leuk Res 2019, Blood Advance 2023】

Professor Zhu is at the forefront of developing efficient, low-toxicity leukemia treatment procedures and tailored diagnostic and therapeutic approaches in China.